The Advantages of Outsourcing IRB and IBC Reviews to One Partner
Gene therapy studies are a relatively recent addition to the world of clinical research. As a result, the unique requirements
Gene therapy studies are a relatively recent addition to the world of clinical research. As a result, the unique requirements
As many research organizations are becoming more patient-centric and adapting to technological advancements and remote requirements, they are re-designing the
In an effort to create safe, effective, and affordable ventilators to help combat the foreseeable shortages due to COVID-19, one
A clinical research trial can only be as strong its participant population, but it’s challenging to find eligible patients.
Dawn Wydner, former Food and Drug Administration (FDA) Consumer Safety Officer, LCDR, and current Managing Expert for Advarra’s Quality Center
The year 2021 brought many advancements in the clinical research industry. We’ve pushed for more diversity and inclusion in clinical
Advarra experts Joan Versaggi and Leslie Paul answer questions from the first in the webinar series – FDA Updates: BIMO
Historically, decentralized clinical trials (DCTs) were heralded as the future of patient-centered research. But how can your organization “walk the
Phase I oncology trials present distinct ethical challenges, such as participant vulnerability and the risk of therapeutic misconception, requiring careful oversight.
As March 2020 completely disrupted any sense of normalcy, including in the workplace, many were forced to adapt rather quickly.
As the COVID-19 pandemic has forced a shift toward remote modalities, mobile health (mHealth) technologies have been on the rise.
The discussion on decentralized clinical trials (DCTs) has been brought to the forefront in the wake of the COVID-19 pandemic.